2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Lactate Dehydrogenase

Lactate Dehydrogenase

LDH

Lactate Dehydrogenase

Related Products

PDF 0.33 MB

Lactate Dehydrogenase (LDH) is an enzyme that catalyzes the conversion of pyruvate, the end product of glycolysis, into lactate (and vice versa) with concomitant interconversion of NADH and NAD+. LDH is comprised of two major subunits, LDH-A and LDH-B, which can assemble into five different isoenzymes (LDH1, LDH2, LDH3, LDH4, and LDH5).

LDH-A is also known as the M subunit as it is predominantly found in skeletal muscle, and LDH-B is also known as the H subunit as it is predominantly found in the heart. LDH-A is a vital metabolic enzyme that is associated with cancer development, invasion, and metastasis. LDH-A is also the key player of the Warburg effect. LDH-A has been reported to correlate with clinicopathologic characteristics and survival outcome of multiple cancers. The inhibition of LDH-A has an anti-proliferative effect on primary breast tumors. LDH-B is a crucial glycolytic enzyme that catalyses conversion of lactate and NAD+ to pyruvate, NADH and H+. LDHB plays an important role in autophagy in cancer cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-179680
    RIPK1-IN-38
    		Inhibitor
    RIPK1-IN-38 is an orally active RIPK1 inhibitor with an IC50 value of 27 nM. RIPK1-IN-38 can inhibit the phosphorylation of RIPK1 and its downstream signaling molecules RIPK3 and MLKL. RIPK1-IN-38 exhibits anti-necroptotic activity. RIPK1-IN-38 has excellent anti-inflammatory efficacy in both the SIRS model and GVHD model. RIPK1-IN-38 can be used for the research of inflammatory and immune-related diseases.
    RIPK1-IN-38
  • HY-175230
    ZG-2492
    		Inhibitor
    ZG-2492 is an orally active LDHA inhibitor with an IC50 of 156 nM. ZG-2492 can reduce lactate production and induce cell cycle arrest and apoptosis in pancreatic cancer cells . ZG-2492 has antitumor activity and can be used in the research of tumors such as pancreatic cancer.
    ZG-2492
  • HY-15947G
    Ravoxertinib (GMP)
    		Inhibitor
    Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.
    Ravoxertinib (GMP)
  • HY-118241
    GNE-140
    		Inhibitor
    GNE-140 is an orally active and selective inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression, regulates metabolites of glycolysis and the pentose phosphate pathway, reduces glucose uptake, increases ROS, and induces cancer cell apoptosis. GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer.
    GNE-140
  • HY-128788
    ddhCTP
    		Inhibitor
    ddhCTP is an endogenously produced pyrimidine base analog with a Kd of 17.0 nM for LLDH and an IC50 of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP can be used in studies related to viral infections, COVID-19 and Zika virus infections.
    ddhCTP
  • HY-P2807O
    Lactate Dehydrogenase, Human (E.coli)
    Lactate Dehydrogenase, Human (E. coli) is a recombinant human lactate dehydrogenase (LDH) protein—a redox enzyme that catalyzes the reversible interconversion between lactate and pyruvate. Lactate Dehydrogenase, Human (E. coli) is primarily utilized in life science research, the diagnosis of tissue injury, and as an enzymatic marker.
    Lactate Dehydrogenase, Human (E.coli)
  • HY-165363
    AK-135 hydrochloride
    		Inhibitor
    AK-135 hydrochloride is a Menadione (HY-B0332) derivative. AK-135 hydrochloride restores the electron flow in defective respiratory chain systems. AK-135 hydrochloride decreases LDH release, increases the amount of ATP. AK-135 hydrochloride has a protective effect against myocardial injury.
    AK-135 hydrochloride
  • HY-P2897A
    D-Lactic Dehydrogenase, Staphylococcus epidermidis
    D-Lactic Dehydrogenase, Staphylococcus epidermidis (EC 1.1.1.28) catalyzes the conversion of D-lactate into D-pyruvate while reducing NAD+ to NADH and H+.
    D-Lactic Dehydrogenase, Staphylococcus epidermidis
  • HY-P2807G
    Lactate Dehydrogenase (LDH), Chicken Heart
    Lactate Dehydrogenase (LDH), Chicken Heart (LAD, LD, L-LDH, (S)-Lactate, LDH) is a biological material or organic compound that can be used in life science research.
    Lactate Dehydrogenase (LDH), Chicken Heart
  • HY-N6948S
    Linalyl acetate-d6
    		Inhibitor
    Linalyl acetate-d6 is deuterated labeled Linalyl acetate (HY-N6948). Linalyl acetate is the principal components of many plant essential oils. Linalyl acetate exhibits anti-anxiety, anti-inflammatory, anti-diabetic, anti-stress, and cardiovascular-regulatory effects. Linalyl acetate is orally active.
    Linalyl acetate-d<sub>6</sub>
  • HY-W013032R
    Oxamic acid (Standard)
    		Inhibitor
    Oxamic acid (Standard) is the analytical standard of Oxamic acid. This product is intended for research and analytical applications. Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis[1][2][3].
    Oxamic acid (Standard)
  • HY-181015
    α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu
    		Inhibitor
    α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu (Compound C) is an oligosaccharide. α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu activates the PI3K/AKT signaling pathway. α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu significantly inhibits Apoptosis by regulating the Bcl-2/BAX ratio. α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu shows cytoprotective activity by reducing ROS and LDH levels, decreasing MDA activity, and increasing CAT, SOD, and GSH activities. α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu shows neuroprotective effects and antioxidant capacity.
    α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu
  • HY-P2807J
    L-Lactate Dehydrogenase (L-LDH), pig muscle
    L-Lactate Dehydrogenase (L-LDH), pig muscle is an L-lactate dehydrogenase found in pig muscle, mainly present in anaerobic tissues (skeletal muscle, red blood cells). L-Lactate Dehydrogenase (L-LDH), pig muscle can interact with acidic liposomes at low pH, causing protein to adsorb onto the liposomes and inhibit enzyme activity. The IC50 values for L-Lactate Dehydrogenase (L-LDH), pig muscle are 0.05 μM for cardiolipin and 1.3 μM for phosphatidylserine liposomes.
    L-Lactate Dehydrogenase (L-LDH), pig muscle
  • HY-161279
    Antibiofilm agent-5
    		Inhibitor
    Antibiofilm agent-5 (compound 6c) is a multitargeting antibacterial agent with potent antibiofilm activity. Antibiofilm agent-5 could induce metabolic dysfunction by deactivating lactate dehydrogenase and promote the accumulation of reactive oxygen species to decrease the reduced glutathione and ultimately cause oxidative damage in bacteria. Antibiofilm agent-5 can be used for the research of refractory biofilm-intensified bacterial infections.
    Antibiofilm agent-5
  • HY-101374
    AGN 192403
    		Inhibitor
    AGN 192403 (BRD4780) is a potent and selective imidazoline-1 receptor antagonist with a Ki value of 42 nM. AGN 192403 is also a TMED9 inhibitor. AGN 192403 shows protective effects on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. AGN 192403 mitigates the proliferation and migration of differentiated glioma tumor cells. AGN 192403 can be used for glioma tumor and neurological diseases research.
    AGN 192403
  • HY-131485A
    3-Acetylpyridine adenine dinucleotide, 95%
    		Inhibitor
    3-Acetylpyridine adenine dinucleotide, 95% (3-APAD, 95%)is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 95% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite.
    3-Acetylpyridine adenine dinucleotide, 95%
  • HY-169060
    LDHA-IN-8
    		Inhibitor
    LDHA-IN-8 (Compound 6) is a lactate dehydrogenase (LDHA) inhibitor. LDHA-IN-8 inhibits LDHA catalysis of pyruvate in a dose-dependent manner (EC50 value of 14.54 μM), reduces intracellular lactate levels, and increases intracellular reactive oxygen species (ROS) levels, thereby inhibiting the proliferation of pancreatic cancer cells and lung cancer cells. LDHA-IN-8 holds promise for research in the field of LDHA-related antitumor therapies.
    LDHA-IN-8
  • HY-W040073S
    Nifurtimox-d4
    		Inhibitor
    Nifurtimox-d4 is deuterium labeled Nifurtimox. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
    Nifurtimox-d<sub>4</sub>
  • HY-P2807N
    Chemically modified Porcine L-Lactate Dehydrogenase
    Chemically modified Porcine L-Lactate Dehydrogenase catalyzes the interconversion of L (+)-lactate to pyruvate.
    Chemically modified Porcine L-Lactate Dehydrogenase
  • HY-154866
    Anticancer agent 122
    		Inhibitor
    Anticancer agent 122, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research.
    Anticancer agent 122
Cat. No. Product Name / Synonyms Application Reactivity